Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

27.29
+5.5525.50%
Post-market: 27.20-0.0900-0.33%15:23 EST
Volume:3.62M
Turnover:94.30M
Market Cap:2.89B
PE:-17.37
High:27.38
Open:22.44
Low:22.16
Close:21.75
52wk High:30.48
52wk Low:10.60
Shares:105.87M
Float Shares:60.53M
Volume Ratio:2.30
T/O Rate:5.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5708
EPS(LYR):-1.4480
ROE:-30.02%
ROA:-20.66%
PB:5.17
PE(LYR):-18.85

Loading ...

Top Midday Gainers

MT Newswires Live
·
3 hours ago

Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal

MT Newswires Live
·
3 hours ago

BUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial

Reuters
·
Yesterday

Update: Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial

MT Newswires Live
·
Yesterday

BRIEF-Edgewise Therapeutics Inc On Track To Deliver Full 12-Week Part D Readout In 2Q 2026 And Phase 3 Start In 4Q 2026

Reuters
·
Yesterday

Edgewise Therapeutics Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial

Reuters
·
Yesterday

Edgewise Therapeutics Inc - Completes Phase 2 Parts B and C of Cirrus-HCM

THOMSON REUTERS
·
Yesterday

Edgewise Therapeutics Inc: on Track to Deliver Full 12-Week Part D Readout in 2Q 2026 and Phase 3 Start in 4Q 2026

THOMSON REUTERS
·
Yesterday

Edgewise Therapeutics Inc - Edg-7500 Well Tolerated With No Significant Lvef Reductions

THOMSON REUTERS
·
Yesterday

Edgewise Therapeutics (EWTX) Is Up 8.2% After Advancing Muscle Pipeline And Leadership Shift Toward Launch

Simply Wall St.
·
Dec 22

BRIEF-Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules

Reuters
·
Dec 02

Edgewise Therapeutics Grants Stock Options to New Employee Under Inducement Plan

Reuters
·
Dec 02

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Dec 02

Edgewise Therapeutics Files Initial Beneficial Ownership Statement for Director Christopher Nathan Martin

Reuters
·
Nov 25

Edgewise Therapeutics Appoints Christopher Martin to Board of Directors

Reuters
·
Nov 20

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to Its Board of Directors

THOMSON REUTERS
·
Nov 20

Edgewise Therapeutics Q3 Operating Expenses USD 46.858 Million

Reuters
·
Nov 20

Edgewise Therapeutics (EWTX): Assessing Valuation After Clinical Progress and New CFO Appointment

Simply Wall St.
·
Nov 19

Edgewise Therapeutics (EWTX) Gets a Buy from Evercore ISI

TIPRANKS
·
Nov 18

Edgewise Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 14